ILM1.DE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 11:36):

Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments...

Stats
Today's Volume	9 976.00
Average Volume	39 334.00
Market Cap	335.66M
EPS	€0 ( 2024-03-26 )
Next earnings date	( €0 ) 2024-05-06
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	17.85
ATR14	€0.0500 (0.36%)

Volume Correlation

Long: 0.10 (neutral)

Short: 0.68 (moderate)

Signal:(38.366) Neutral

Medios AG Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Medios AG Correlation - Currency/Commodity

-0.46
( neutral )

-0.53
( weak negative )

0.00
( neutral )

-0.34
( neutral )

-0.19
( neutral )

0.55
( weak )

Medios AG Financials

Annual	2023
Revenue:	€1.78B
Gross Profit:	€51.94M (2.91 %)
EPS:	€0.790

Q4	2023
Revenue:	€441.25M
Gross Profit:	€11.24M (2.55 %)
EPS:	€0.100

Q3	2023
Revenue:	€489.94M
Gross Profit:	€28.80M (5.88 %)
EPS:	€0.300

Q2	2023
Revenue:	€422.28M
Gross Profit:	€26.13M (6.19 %)
EPS:	€0.190

Financial Reports:

No articles found.

Medios AG

Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.